Drug Trial Radar · NCT07294235
A Study of BGM1812 Injection in Healthy and Non-diabetic Overweight or Obese Chinese Participants
Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
60
Actual
Start
Dec 5, 2025
Primary completion
Jun 5, 2026
Study completion Jun 5, 2026
Sponsor
- Lead sponsor
- BrightGene Bio-Medical Technology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 19, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the tolerability , safety and pharmacodynamics of BGM1812 administered subcutaneously in healthy and non-diabetic overweight or obese Chinese participants, and to investigate the pharmacokinetic profile of BGM1812 in the bloodstream.
Conditions
- Overweight or Obesity
Interventions
BGM1812Drug
AdministeredSC
PlaceboDrug
Administered SC
BGM1812Drug
Administered SC
PlaceboDrug
Administered SC
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with One or More Adverse Events (AEs) and Serious Adverse Event(s) (SAEs) Considered by the InvestigatorTime frame: Baseline to Study Completion (Up to 6-9weeks)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Yunnan University of Chinese Medicine
Kunming, Yunnan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.